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Abstract
The proper allocation of public health resources for research and control requires quantification of both a disease’s current
burden and the trend in its impact. Infectious diseases that have been labeled as ‘‘emerging infectious diseases’’ (EIDs) have
received heightened scientific and public attention and resources. However, the label ‘emerging’ is rarely backed by
quantitative analysis and is often used subjectively. This can lead to over-allocation of resources to diseases that are
incorrectly labelled ‘‘emerging,’’ and insufficient allocation of resources to diseases for which evidence of an increasing or
high sustained impact is strong. We suggest a simple quantitative approach, segmented regression, to characterize the
trends and emergence of diseases. Segmented regression identifies one or more trends in a time series and determines the
most statistically parsimonious split(s) (or joinpoints) in the time series. These joinpoints in the time series indicate time
points when a change in trend occurred and may identify periods in which drivers of disease impact change. We illustrate
the method by analyzing temporal patterns in incidence data for twelve diseases. This approach provides a way to classify a
disease as currently emerging, re-emerging, receding, or stable based on temporal trends, as well as to pinpoint the time
when the change in these trends happened. We argue that quantitative approaches to defining emergence based on the
trend in impact of a disease can, with appropriate context, be used to prioritize resources for research and control.
Implementing this more rigorous definition of an EID will require buy-in and enforcement from scientists, policy makers,
peer reviewers and journal editors, but has the potential to improve resource allocation for global health.
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Introduction
Infectious diseases are a significant threat to global health in the
21st Century, causing significant morbidity and mortality, and
economic loss [1]. However, the allocation of funding to research
and control diseases is often based on subjective assessment, rather
than rigorous estimates of the total current and anticipated disease
burden, leading to large mismatches between impact and
allocation [2,3]. In addition, some diseases are labeled as
‘‘emerging’’ following an initial outbreak, but which cause
relatively little public health impact subsequently, often garner
significant attention and resources (e.g. hantavirus pulmonary
syndrome in the USA; see below). Emerging diseases are generally
considered those that have recently increased in impact, moved
into new geographic regions, moved into human hosts for the first
time, changed their clinical presentation with more severe
symptoms, or are caused by newly evolved pathogens
[4,5,6,7,8,9,10,11,12,13]. These ‘‘emerging infectious diseases’’
or ‘‘EIDs’’ have become the focus of national [14], regional and
global [15,16,17,18,19] control programs.
Despite heightened interest in EIDs and frequent use of the
term ‘‘emerging’’ to draw attention to a disease, its use is
subjective, inconsistent and incomplete and rarely is based on a
reproducible quantitative analysis of the trend in impact.
Developing a consistent and reproducible definition to EIDs is
not simply a semantic issue because proper designation of a disease
as ‘‘emerging’’ implies an increased impact in the future and is
part of a valid utilitarian approach to determine the importance of
different diseases and to the allocation of scarce public health
resources [20]. An accurate and quantitative description of the
trend in a disease’s impact would thus allow public health
managers to better define which disease are highest priority, and
also to determine when an EID becomes endemic, or recedes in
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impact, so that resources could be allocated to other public health
threats.
A rigorous analysis of trends in disease impact must overcome
several challenges. First, authors usually do not put temporal
bounds on emergence so that diseases for which incidence
increased in a prior period, but is now diminishing, are still
considered ‘emerging’. Although an influential review from the
Institute of Medicine suggested a timescale of 20 years [8] over
which to examine patterns of incidence, this is an arbitrary length,
and regardless, defined time limits have rarely been used. Second,
most previous studies do not quantify geographic variation in the
change in incidence or impact. The key point is that to quantify
the trend in the impact of a disease, we must define the population
in which a disease is proposed to be emerging and the time period
over which emergence has or has not occured.
In this paper, we illustrate a simple, reproducible and
quantitative method to add objectivity to previous definitions of
emergence [4,5,6,7,8,9,10,11,12,13] based on a statistical analysis
that can be applied to time series, including incidence data, or,
preferably, measures of disease impact such as Disability Adjusted
Life Years (DALYs). Our goal is to highlight the value of
considering the trend in a disease’s impact and by doing so add a
measure of rigor to the term ‘‘emerging’’ which will restore it as an
important and useful descriptor of a growing set of infectious
diseases. In addition, several recent studies have aimed to uncover
the trends and factors that cause the emergence of diseases
[4,21,22] and these studies require identification of the point in
time that a disease begins to emerge within a region and
population. The analyses we describe provide a way to identify
this point in time and will thus provide a way to better analyze the
process of disease emergence.
Methods
To develop a quantitative definition of disease emergence,
trends in incidence (the number of cases a disease produces in a
defined population within a given time period) or public health
impact (which can be measured in a number of ways, e.g.
mortality, morbidity, or DALYs) must be examined over a given
time period and in a defined population. The simplest method for
quantifying trends in disease incidence or impact is a linear
regression with time as the predictor. This produces an increasing
(emerging) or decreasing (recending) slope, or no significant
change (stable) in incidence in the population over the time period
examined. For diseases that have undergone changes in trends, an
additional tool for examining time series, segmented linear
regression, can be used. The model can be written as
E½yDx~b0zb1xzd1(x{t1)w1z:::zdk(x{tk)wk
Where y are the incidence data, x is time, b0 is the intercept, b1 is
the initial slope, the tk are the unknown points of inflection (or
joinpoints), dk are the changes in slope after the inflection point,
and the wk are 1 if (x-tk).0, and 0 otherwise to ensure continuity
at joinpoints. We determined the best fitting number and location
of joinpoints by exhaustively exploring each year in the time series
as a joinpoint. We tested whether a model with 1 or more
joinpoints fit better than a null model that had fewer joinpoints
(beginning with zero). We compared models using a permutation
method in which the residuals of the null model (for 0 joinpoints
the null model is a simple linear regression) are repeatedly
permuted (randomly reordered) and added to the predicted values
from the null model to generate thousands of permuted data sets
[23]. The alternative model with additional joinpoints is then fit to
the permuted data sets and the distribution of a goodness-of-fit
measure (in this case an F-statistic or a simpler monotonic
transformation of the F-statistic) is obtained. The alternative model
with more joinpoints is favored if the improvement in goodness of
fit against the null model obtained by fitting to the original data is
highly unlikely; i.e. it is in the upper 5% percentile of all the
improvements in goodness of fit on the permuted datasets. The
method is conservative in the sense that in a situation where the
data are not informative, the simpler model is chosen. This
approach to select the number of joinpoints was developed to
detect changes in trends in cancer rates [23].
To illustrate this approach we analyzed yearly incidence data
for twelve diseases from the GIDEON database [24] from 1961
until 2010. GIDEON collates referenced data for 349 infectious
diseases worldwide. Although GIDEON data contain some
inaccuracies, they provide useful illustrations of the patterns that
arise most frequently with case data. We performed segmented
regression using a maximum of 2 joinpoints, a minimum of 5 years
between joinpoints (both of which are arbitrary), 1000 permuta-
tions and an overall significance threshold of 0.05 with Bonferroni
correction. We used an identity link function and assumed the data
were Poisson distributed, and classified a disease as emerging or
receding if, over the period between joinpoints, the slope was
significantly greater or less than 0, respectively, with a significance
threshold 0.05 using a z-test. The method was implemented in
C++, and fitting was done using Levenberg-Marquardt nonlinear
least squares. An independent GUI-based implementation of the
method is available [25], and a similar method (based on iterative
fitting) has been implemented in the open-access segmented package
in R [26]. Recent work suggests that comparing among models
with different joinpoints is best done either with the permutation
method above, or with Bayesian Information Criterion, both of
which are more conservative than Akaike’s Information Criterion
which often leads to overfitting [27].
The best fitting joinpoints (points of inflection) are estimates of
the beginning of an emergence or receding event. Additionally,
disease ‘‘re-emergence’’ can be rigorously defined using this
approach. For a disease to be re-emerging, the incidence or impact
of a disease must be shown to increase initially (the first emergence
event), then either stabilize or recede, and then increase again (the
re-emergence). These patterns are illustrated with actual incidence
data below.
Results
There were six patterns apparent in trends of disease incidence
that likely capture most of the variation that is likely to occur. First,
incidence trends for several diseases show simple and relatively
consistent increases and are characterized as emerging (e.g. Lyme
disease in temperate countries over the past three decades; Fig. 1a,
S8; Brucellosis in some regions; Fig. S1 in File S1; Rabies in China
1995-present; Fig. S10 in File S1). Second, others show simple
monotonic decreases and are clearly receding (African Trypano-
somiasis, Tanzania; Fig. 1b). Third, a smaller subset of diseases
show an initial significant increase in incidence, a decrease, and
then a significant increase, which, as noted above, fits our
definition of a ‘re-emerging’ disease (Rocky Mountain Spotted
Fever in the USA; Fig. 1c, S11). Fourth, case loads for many
diseases show a receding incidence following a previous increase
(Salmonellosis in Europe; Fig. 1d, S12 in File S1; Hepatitis B in
Europe; Fig. S5 in File S1) and therefore should no longer be
described as EIDs. Fifth, case loads for some diseases show an
initial increase, then a further increase in the slope (Dengue in
Asia, Fig. 1e, and elsewhere, Fig. S3 in File S1). These diseases
Defining an Emerging Infectious Disease
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could be considered to have undergone two phases of emergence
without an intervening receding period. Finally, for some diseases
there are no significant trends in a given population over a time
period identified as distinct via segmented regression, given year-
to-year variability (Leptospirosis, Oceania, 1985–2010; p.0.05;
Fig. 1f ; Crimean-Congo hemorrhagic fever in Bulgaria and
Africa, Fig. S2 in File S1; Hantavirus pulmonary syndrome in the
USA, Fig. S4 in File S1). For these diseases there is no evidence for
current emergence or receding and they can be termed either
stable (if fluctuations are small), non-trending (if fluctuations are
large) or if the time series is short, data lacking. Although most of
the patterns in Figure 1 are evident upon visual inspection (they
were selected to be exemplary), many patterns are not as clear and
rigorous analysis is needed to determine the significance of a trend
(e.g., the non-significant trend in Fig. 1f, the second increase in
incidence of Hepatitis C in Brazil, Fig. S6 in File S1)
It is worth noting that for many diseases, there can be strongly
opposing trends in different regions, and in some cases, depending
on the population considered. For example, Plague is receding in
Brazil and the Americas but is emerging in the Democratic
Republic of Congo (Fig. S9 in File S1).
The elevation and trend of a fitted relationship also indicate the
relative potential impact of EIDs. For example, while Legionellosis
(Fig. S7 in File S1) is emerging in both Europe and the Americas
(with similar trends or slopes), the case load is twice as high in
Europe, and, all else being equal, greater investment to combat
this disease in the population where the case load is higher is
warranted. This assumes investment is allocated on the basis of the
total number cases rather than the fraction of the population
affected, which seems preferable. Similarly, the number of Lyme
cases in Poland is both higher and is increasing at a greater rate
than in the Czech Republic (Fig. S8 in File S1), which suggests a
greater urgency for additional efforts to combat this disease in
Poland. These examples use trends in two populations for the
same disease to make a valid comparison. Comparing different
diseases would require a common currency, such as DALYs.
This approach also provides a way to examine the initial time
points of emergence. For example, Legionellosis showed a sharp
rise in case numbers in several regions between 1995 and 2001
(Fig. S7 in File S1). If changes in case definitions and detectability
of cases can be ruled out, underlying factors that led to emergence
during this period might be identified. Alternatively, investigating
the cause for a significant rise in cases (i.e., events occuring at a
joinpoint) might help in identifying a change in reporting that
falsely gives the impression of disease emergence.
Discussion
Our approach provides a simple method to define a disease as
emerging, re-emerging, receding or non-trending, and to describe
the magnitude of the rate of change. It provides a tool to
implement the conceptual ideas behind previously proposed
definitions that were too vague to be widely adopted. If this new
method is embraced by the scientific and public health commu-
nity, it should be possible to overcome the subjective definitions of
EIDs used previously and regain the utility of designating diseases
as emerging or not.
Our results highlight two key issues. First, the designation of a
disease as emerging implicitly refers to longer-term trends than an
individual outbreak or epidemic. Data on a yearly timescale is
most likely appropriate for decisions involving funding for
research, and non-emergency control measures. Most previous
studies have not defined the time window over which a disease
must increase in incidence to be defined as emerging. This has led
to confusion over the terms ‘‘emerging’’ and ‘‘re-emerging’’, and
the exclusion of the latter from some analyses [4,22,28,29]. Our
analysis identifies the temporal window (timescale) for a trend
statistically rather than arbitrarily, and characterizes trends across
the whole time series such that a disease can emerge and re-
emerge multiple times depending on the time period of interest.
Secondly, by focusing on a specific, defined population (and by
inference, in most cases a geographic region), the analysis provides
a more general way of defining an EID than previous studies.
Following our approach, diseases can emerge within a population
that is a subset of a larger but spatially contiguous population (e.g.,
a racial group, a gender, a behavioral group, etc.), or within a
region (in which case a disease is emerging within that region) or in
all humans (in which case the disease is globally emerging). This
implies that a disease can be classified as an EID in one population
at one scale and be stable or receding in another at a different scale
[30]. While this is implied in many studies of EIDs, our approach
removes contradictions and ambiguities arising from trying to
determine whether disease is either emerging, or not, in all regions
at any time.
One issue which merits discussion is the emergence of diseases
associated with spatial spread to new regions. Our framework for
detecting trends in temporal data (time series) does not directly
address spatial spreading of diseases, but it can still provide a
broad perspective of temporal trends. For example a disease may
invade a new region and fade out (Monkeypox in the USA [31]) or
it may become endemic, but with no significant increase in
Figure 1. Patterns of incidence illustrating some of the possible
outcomes of the proposed analytical framework. A) emergence,
b) receding, c) re-emergence, d) receding after emergence, e)
emergence and further emergence, f) receding, emergence, stability.
Segments in red show significantly positive slopes for that time period,
segments in green show significantly negative slopes, and segments in
yellow indicate a non-significant trend (p.0.05).
doi:10.1371/journal.pone.0069951.g001
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incidence after its invasion of the new region is complete (e.g. West
Nile virus in North America from 1999–2012 [32]). Thus, while
the spatial spread of these two pathogens is consistent with the
definition of an EID that includes the spread of a pathogen to a
new region, our framework indicates that neither of these diseases
has continued to emerge (i.e. increase in incidence or impact)
following their initial spread.
Studies which aim to analyze trends in disease emergence, or
the factors that cause them to emerge, require identification of the
point in time that a disease first emerges within a population or
region [4,21,22]. Identifying the precise timing of initial
emergence events (i.e., the first few cases of spillover of a novel
zoonotic pathogen) is difficult because there can be a substantial
time lag between the initial infections and detection, especially for
novel diseases in rural or poor populations. For example, evidence
suggests HIV infections occurred for several decades before being
detected [33]. Our approach identifies emergence as the initial
significant rise in incidence or a significant increase in impact and
provides a simple method for estimating the time when emergence
began – the joinpoint of a segmented regression, or the x-intercept
of the initial rise in incidence. It thus provides a strategy to more
accurately analyze global trends in EIDs.
In the current analysis, we used annual incidence data to
determine whether diseases in specified populations were emerg-
ing. If time series data of the impact of diseases are available, and
are quantified in a consistent way (e.g, DALYs), this approach
could be used to analyze diseases that are thought to have emerged
due to increased impact, even without changes in incidence. Our
approach can be easily applied to diseases affecting populations of
plants, wildlife or livestock.
Using a quantitative approach to determine whether a disease is
emerging presents some challenges. First, it requires time series
data in a common currency to accurately classify a disease as
emerging, and to compare the rate or significance of emergence
among different diseases. The ideal would be time series of DALYs
for each disease. While this is a challenge for analyzing some
historical trends, we believe it is a strength, in that it brings rigor to
the analysis. Second, surveillance data, like those used in our
example analyses, are influenced by changes in reporting, case
definitions, diagnostic capabilities, and other aspects that deter-
mine the measured case burden. Third, simple measures like case
numbers may be a poor measure of disease impact, especially if
populations have different resources for treatment (e.g. AIDS in
the USA vs. Africa). As a result, more explicit measures of disease
burden should be used whenever possible. Fourth, although we
have presented a simple approach based on segmented linear
regression, nonlinear approaches may be more appropriate for
some data (e.g. Fig. S5 in File S1, Hepatitis B Worldwide).
Translating the results of analyses of trends in disease impact
into policy requires careful thought. While the elevation and slope
of trends in disease impact provide useful information about the
potential impact of a disease in the near future, using trends to
predict future impact clearly assumes that past trends will
continue, and should be interpreted in the context of current
control efforts. For example malaria eradication campaigns have
been highly successful in several countries, and analyses of case
burdens show strongly receding trends [34]. Diversion of funds
away from locations where public health resources are effectively
suppressing disease transmission is likely to lead to re-emergence.
Specifically, reducing control measures before eradication cam-
paigns are complete due to low and declining case loads is counter-
productive. Clearly, the effort and resources currently invested in a
disease in a specific population, and the impact of changes in
resources allocated on case burdens is required to properly
interpret a trend in disease impact.
In summary, over the past two decades, there has been a
proliferation in the use of the term ‘‘emerging infectious disease’’,
without a simple and repeatable method to assess emergence. We
have proposed a simple quantitative framework to designate a
disease as emerging, re-emerging, receding or stable/non-trending
and to facilitate comparisons among burdens and trends in
different regions, populations and among diseases. This approach
allows for the identification of time points associated with changes
in case burden that can be used to try to determine the causes of
disease emergence. We hope that, with increasingly accurate
surveillance data, and given the appropriate context, a quantitative
approach like the one suggested here could improve prioritization
of resources for infectious disease research, surveillance and
control. Implementing this more rigorous definition of an EID will
require buy-in and enforcement from scientists, policy makers,
peer reviewers and journal editors. Implementation faces signif-
icant challenges because doing so will often demonstrate that little
evidence exists to support a claim that a favored disease is in fact
emerging.
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